Clinical research
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 24, 2020.
Relugolix is a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist.
With phase III trials underway and Fast Track designation from the FDA, “It’s, conservatively, at least one year ahead of everyone else’s,” John Temperato, president and CEO, told BioSpace.
Ridgeback Therapeutics will launch two mid-stage programs assessing the efficacy of its antiviral candidate EIDD-2801 as a treatment for COVID-19.
Merck’s investigational pneumonia vaccine, V114, hit the mark in two Phase III studies, including one involving adult HIV patients.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 22, 2020.
The TACTIC-E trial will investigate the safety and efficacy of experimental therapies designed to prevent and treat life-threatening complications associated with COVID-19 in hospitalized patients who are at early stages of the disease.
It was a busy week for clinical trial announcements. Here’s a look.
According to a BioPharma Dive report, since March, more than 100 biopharma companies announced their clinical trials were disrupted in some way because of the pandemic.
The company indicated the initial data was promising, but the data for overall survival benefit and additional secondary endpoints were not yet mature and the trial will continue.
PRESS RELEASES